– USA, NJ – Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company today announced the appointment of Frank Karbe to its Board of Directors.
“We are thrilled to welcome Frank to our Board as we approach a critical inflection point for Phathom. Frank’s financial, business development, and corporate strategy expertise and strong record of readying organizations for commercialization will help guide the execution of our strategic vision,” said CEO, Terrie Curran.
About Frank Karbe
Mr. Karbe, who most recently served as President and CFO of Myovant Sciences, Inc. (NYSE: MYOV), brings over twenty-five years of financial and life-sciences expertise to Phathom.
As President and CFO of Myovant, Mr. Karbe led the company’s efforts to raise approximately $2 billion in capital and its evolution from a private start-up organization to a publicly listed commercial-stage company with two approved and marketed products. Before Myovant, Mr. Karbe served as EVP and CFO at Exelixis, Inc. (Nasdaq: EXEL), where he drove the biopharma company’s transformation from discovery to commercialization. Earlier in his career, he worked as an investment banker for Goldman Sachs & Co. focusing on corporate finance and mergers and acquisitions in the life sciences industry. Mr. Karbe has previously served on the Board of Directors of Aduro Biotech, Arbutus Biopharma Corporation, and Kolltan Pharmaceuticals, Inc.
Mr. Karbe holds a Diplom-Kaufmann from the WHU Otto Beisheim School of Management in Koblenz, Germany.
About Phathom
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker in late-stage development for the treatment of acid-related disorders.
For more information: https://www.phathompharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
